ArticleScientific reports2026
Chitosan-EDTA-cellulose functionalized with β-cyclodextrin as a pH-sensitive bio-based nanocarrier for curcumin drug delivery.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In this work, chitosan/cellulose/β-cyclodextrin nanostructure was synthesized by cross-linking chitosan and cellulose with EDTA followed by bridging with ethylenediamine-β-cyclodextrin. The chitosan/cellulose/β-cyclodextrin bio-based nanostructure is a novel drug delivery system that has been developed for the delivery of hydrophobic drugs. The chitosan/cellulose/β-cyclodextrin nanostructure was characterized by EDX, XRD, FESEM, TGA, FT-IR, in vitro drug loading and release study. The drug efficiency of the curcumin inclusion complex with chitosan/cellulose/β-cyclodextrin was higher compared to chitosan-EDTA-cellulose and increased with increasing β-cyclodextrin fragments. The curcumin release behavior from chitosan-EDTA-cellulose and chitosan/cellulose/β-cyclodextrin nanostructures was evaluated at two pHs of 5.5 (acidic extracellular microenvironment of tumors) and 7.4 (typical physiological pH of most body tissues and fluids) in 72 h, which was better fitted with the Korsmeyer's-Peppas kinetic model. The cytotoxicity of curcumin-loaded chitosan/cellulose/β-cyclodextrin was less than free curcumin. It appeared that the presence of β-cyclodextrin appreciably reduced the burst release observed in chitosan-EDTA-cellulose network. Finally, chitosan/cellulose/β-cyclodextrin was obtained with nanoparticle size of about 56.07 ± 12.11 nm, zeta potential range of 31.26 ± 0.09 to 47.98 ± 0.11 mV, and encapsulation efficiency of 86.0 ± 0.17%. The outcomes indicated that the chitosan/cellulose/β-cyclodextrin nanostructure is applicable for the parenteral injection delivery of the curcumin anticancer drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.